Home - Objective Insights

Business Analysis for the Health Care Industry

Objective Insights is a consulting firm dedicated to providing health care companies with the marketing and financial analysis they need to make informed decisions about their business opportunities.

Long-Term Forecaster™ (LTF)

OI TOOL

• Easy-to-use strategic forecasting model
• Based in Microsoft Excel
• Forecasts out to 20 years; includes expenses for full P&L
• Detailed treatment of development timeline, expenses, and probabilities
• Handles deal terms so you can model partnering
• Built-in Monte Carlo simulation for risk analysis

Short-Term Forecaster™ (STF)

OI TOOL

• Trend-based short-to-medium range demand forecasting model
• Based in Microsoft Excel
• Built-in trending for one-click forecast generation
• Easy-to-use events to handle current & future effects not in trend
• Shows prediction intervals and includes Monte Carlo simulation for risk analysis

Patient Dynamics Forecasting

OI SERVICES

• Forecasting complicated or progressive diseases
• Uses Objective Insights Long-Term Forecaster™ model
• Driven by hazard curves from clinical trials and disease registries
• Properly handles mortality, progression, and drug persistence
• Parametric, transparent, and easy to use
• Determines patient flows and prevalence in each state

What We Do

Capabilities

We combine industry experience, powerful analytical techniques, and sophisticated models to generate insights and understanding which lead to a decision that is right for you.

About Us

Team

Clients

We are highly experienced in business analytics, due to our educations, our prior employment at Biogen, Merck, and Syntex, and our decades of consulting.

Contact Us

Contact

Company principals work on all projects. Contact Objective Insights today so that we can discuss how we can help you.

OI XXV Years — OI Celebrating More than 25 Years of Exceptional Service

I have used Objective Insights’ services for many years, first at Gilead and now at XenoPort. I am impressed with their analytical ability, forecasting models, and customer service. At XenoPort, we have a product that has faced a number of changes over the last few years, and sometimes the performance data aren't even pointing in a consistent direction. Throughout the evaluation process, Objective Insights’ forecasts have been remarkably accurate in predicting prescriptions and revenues. Objective Insights' thoughtful and thorough approach gives us confidence in our planning process and makes our jobs less stressful.

William Harris

Senior Vice President of Finance and Chief Financial Officer / XenoPort

I have worked with Objective Insights several times over the years while in strategic marketing roles at various biotech and pharmaceutical companies. Each time I work with them, Charley, Brett, and colleagues deliver a top quality job, whether on a qualitative, quantitative, or strategic project. In either case, they are on time and budget and make my life easier by producing detailed, accurate, and insightful work that provides lasting value to the organization. Their work is not put away on a shelf and forgotten; instead, it is used again and again as a relevant and useful reference. When working with Charley and Brett, I know I don't have to worry about the results, they are guaranteed to be excellent. Without hesitation, I have Objective Insights my highest recommendation.

Sally Meadows

Senior Director, Inflammation Disease Area Strategy / Roche

I have known and worked with the principals of Objective Insights for over 20 years. Objective Insights has provided forecasting models for the Marketing, New Product Planning, and Business Development functions at Jazz Pharmaceuticals. Their expertise in building reliable forecasting models and their knowledge and ability to populate them with key assumptions is commendable. We have all been very impressed with their commitment to customer service and ability to meet our aggressive timelines.

Jim Trah

Executive Director, Marketing / Jazz Pharmaceuticals

The entire team at Impax was both extremely happy with the forecasting tool put together by Objective Insights and the speed with which the tool was delivered. We could not have asked for a more knowledgeable or attentive group, as they were able to quickly address any necessary changes to the model.

Edward DiNapoli

Manager, Business Planning / Impax Laboratories

I have worked with Objective Insights while serving in finance at two companies and have found their expertise in financial modeling and benchmarking critical for my deal evaluations. They provide the support during the deal process that big pharma has in-house. Adding this expertise gives the startup company the edge it needs to strike the best deal possible. Using OI is cost effective and allows us to have top-notch financial models with minimal staff.

Jean Lockhart

Vice President, Finance / Syrrx

We have been impressed with the people of Objective Insights. Their experience with forecasting and analysis and their high quality of work have allowed us to be more confident in our marketing decisions.

Alex Thole

Director of Marketing / Pharmacia

Objective Insights has people with the experience and analytical background to solve complex problems. They helped us think through and quantify the impact of several alternative approaches to a marketing and sales issue. The information was very valuable and helped us make a more informed decision.

John Freeberry

Pricing Strategy Director / AstraZeneca

We think you have performed in an excellent manner and we are very pleased with the deal model and business plan.

Roger Whiting, Ph.D.

Co-founder, President, and Chief Scientific Officer / Roxro Pharma

Our company needed to generate market research data in a particularly short timeframe. Objective Insights was capable of completing our project within a rapid turn-around time. They were quick to assimilate our specific business needs and developed the appropriate survey tools to capture the information we required. Objective Insights demonstrated a keen knowledge of the healthcare marketplace and proved to be a valuable partner on this project.

Brad Zakes

Chief Executive Officer / Cerevast Therapeutics

Your models are the most comprehensive I've seen in the industry, and currently the most useful standalone valuations platform.

Michael Emery

Associate Director of Forecasting, Financial Planning & Analysis / Rapid-growth specialty pharmaceutical company

Your models are great and have given us an advantage.

Michael Bury

Associate Director / Gilead Sciences

I found the model such a wonderful tool that saves me so much time with assumption changes. I wish I would have found this model earlier and I think it could have saved a tremendous amount of my time or my team's time for building forecast models and all the demanding QC. I just wanted to say thank you for creating such a great tool!!

Yeon Kang

Associate Director, New Product Planning / Impax Pharmaceuticals

Charley and Brett do a great job in understanding our needs, and then use this to build useful, streamlined models.

Asmita Karandikar

Manager, National Analytics & Forecasting / Gilead Sciences, Inc.

I love working with your models. They take away all the work and additional calculations that are typical with forecasts. You have thought of every issue with forecasts (price increases, market growth, and share trends) and make updating assumptions easy and user friendly. I wish everyone (all of my clients) would use Objective Insights models to create forecasts.

Katherine Timoney

Hutchinson Marketing Solutions

Finally, a consultant that understands our business!

Abigail Jenkins

Senior Director, RSV Marketing / MedImmune

The team at Objective Insights is a pleasure to work with. They are extremely knowledgable, staying abreast of the latest industry developments. Customer service is top-notch and their support after the sale is outstanding.

Erik Fredrickson

Forecasting Manager / Genentech

The pricing research and analysis that we recently completed with Objective Insights’ help has been described by some at AstraZeneca as the best research we’ve ever done.

Barnabas Desta

Pricing Strategy Manager / AstraZeneca Pharmaceuticals